6 February 2019 - Vertex has revealed financial figures that are likely to go down well with investors, but not patients in the UK who are eligible to receive the revolutionary drugs like Orkambi yet are being denied access because of an ongoing row with NICE.

The UK is an important market for Vertex because of its large number of cystic fibrosis (CF) patients– it’s estimated that more than 10,000 patients have the disease in the country, the second largest patient population in the world.

But in a call with investors chief commercial officer Stuart Arbuckle said that the company is unwilling to submit files to NICE, which assesses the cost-effectiveness of drugs in England, and in most cases Wales and Northern Ireland.

Read Pharmaphorum article